Schrodinger Inc (NASDAQ:SDGR) is one of the best long-term stocks to invest in according to Bill & Melinda Gates Foundation Trust. The stock is backed by 31 hedge funds. Schrodinger shares are up around 13% over the past month, and **** ysts see more upside in the stock.
On June 9, Schrodinger Inc (NASDAQ:SDGR) announced it had finalized a transition, separation, and release of claims agreement with Mannix Aklian, its former Chief Commercial Officer and Global Head of Software Sales and Marketing.
Schrodinger Inc is transitioning its platform to a hosted software licensing model, and the management has said good progress is being made on this front. In its Q1 2026 results, released on May 5, Schrodinger reported a 12% YoY increase in annual contract value (ACV) to $28.4 million. The company said the growth in contract value in that quarter was driven by new deployments and usage scale-ups.
Software revenue was down 21% as the transition to hosted software licensing accelerated. Drug discovery revenue more than doubled to $22.9 million due to continued progress in Schrodinger's collaboration portfolio.
Looking ahead, the company anticipates Q2 2026 ACV in the range of $19 million to $23 million. For the full-year 2026, it expects ACV in the band of $218 million to $228 million, reflecting a growth of 10% to 15%. Schrodinger anticipates drug discovery revenue between $55 million and $65 million in 2026. The company said that Lilly's planned acquisition of Ajax Therapeutics validates the strength of its platform.
On June 9, Schrodinger Inc (NASDAQ:SDGR) announced it had finalized a transition, separation, and release of claims agreement with Mannix Aklian, its former Chief Commercial Officer and Global Head of Software Sales and Marketing.
Schrodinger Inc is transitioning its platform to a hosted software licensing model, and the management has said good progress is being made on this front. In its Q1 2026 results, released on May 5, Schrodinger reported a 12% YoY increase in annual contract value (ACV) to $28.4 million. The company said the growth in contract value in that quarter was driven by new deployments and usage scale-ups.
Software revenue was down 21% as the transition to hosted software licensing accelerated. Drug discovery revenue more than doubled to $22.9 million due to continued progress in Schrodinger's collaboration portfolio.
Looking ahead, the company anticipates Q2 2026 ACV in the range of $19 million to $23 million. For the full-year 2026, it expects ACV in the band of $218 million to $228 million, reflecting a growth of 10% to 15%. Schrodinger anticipates drug discovery revenue between $55 million and $65 million in 2026. The company said that Lilly's planned acquisition of Ajax Therapeutics validates the strength of its platform.
5 months ago
